Featured Bioprocessing Editorial
-
FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address
3/17/2026
For those involved in outsourcing, the new FDA draft guidance regarding FDA Form 483 observations reshapes the accountability framework. The public comment period ends May 8.
-
Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
3/17/2026
A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.
-
Where Contamination Control Really Breaks Down In Practice
3/13/2026
Contamination control gaps arise when two dynamics merge — when processes become familiar and workloads increase. Here's how to spot them before they spin out of control.
-
Trends In FDA FY 2025 Warning Letters
3/13/2026
The FDA issued a total of 303 warning letters to drug and biologics products in Fiscal Year 2025 (FY25), an increase from FY24. This article reveals key agency focal points and trends.
-
SUS Interchangeability Assessment And Qualification Best Practices
3/12/2026
Establishing a robust single-use systems (SUS) interchangeability program can be a pivotal feature of a supply chain resiliency initiative.
-
Accelerating Technology Diffusion In Cell And Gene Therapy
3/11/2026
Unlike most other drugs, advanced therapies require complex, purpose-built supply chain networks. Making them requires cross-sector collaboration.
-
5 QMS Blind Spots You Should Know About
3/6/2026
Companies often underestimate the complexity of standing up an eQMS. These are five of the most common issues that lead to regulatory and GMP exposure risk.
-
New MIT Consortium Links Innovation With Real-World Biomanufacturing
3/6/2026
In one area, the Initiative for New Manufacturing is exploring whether microfactories, championed by the EV industry, can help biopharma iterate facility design faster.
-
Dynamic Flux Analysis Offers Faster Metabolic Modeling Than DOE
2/27/2026
By continuously analyzing spent media, researchers can estimate reaction rates at regular time points, providing a granular view of cell metabolism.
-
Green Supply Chains Rarely Start With A Pledge; Target Waste Instead
2/27/2026
Effective sustainability strategies in pharma supply chains reduce rework and overage. Three leakage points offer the most practical starting point for rooting out waste.